RxDoctor Payments Data

Rob Demuro, MD

Internal Medicine · Elizabethtown, NYNPI 1801893318

Payments from drug & device makers

$883in general payments, 2019–2025

Across 50 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$192
  • Lilly USA, LLC$175
  • Novartis$118
  • AstraZeneca$118
  • Boehringer Ingelheim$86
  • Pfizer$55
  • plus $138 from 5 others

What the payments were for

  • Food & beverage$883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$883 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$40,056
Medicare patients
168
Services billed
486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide177$258,674
EliquisApixaban176$182,847
JardianceEmpagliflozin71$90,686
OzempicSemaglutide40$63,190
FarxigaDapagliflozin Propanediol54$60,858
MounjaroTirzepatide26$46,191
Breo ElliptaFluticasone/Vilanterol79$43,619
JanuviaSitagliptin Phosphate41$43,383
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,339
XareltoRivaroxaban15$23,337
MyrbetriqMirabegron26$17,064
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$16,483
Lantus SolostarInsulin Glargine,hum.Rec.Anlog128$15,245
Spiriva HandihalerTiotropium Bromide15$13,781
TradjentaLinagliptin14$11,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$175$304,865203 claims
PfizerEliquis$55$182,847176 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$86$110,483103 claims
AstraZenecaFarxiga, Symbicort$118$67,72875 claims
Novo NordiskOzempic$53$63,19040 claims
MerckJanuvia$18$43,38341 claims
Johnson & JohnsonXarelto$18$23,33715 claims
AbbVieLinzess$192$10,72119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Elizabethtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →